| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCG2 |
| Uniprot No | Q9UNQ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 557-630aa |
| 氨基酸序列 | NLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGNNPCNYATCTGEEYLVKQGIDLSPWGLWKNH |
| 预测分子量 | 12.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCG2重组蛋白的3篇代表性文献概览(文献信息为示例，具体引用时请核实原文)：
1. **文献名称**：*Structure of the human multidrug transporter ABCG2*
**作者**：Taylor N. et al. (2020)
**摘要**：通过冷冻电镜解析了人源ABCG2重组蛋白的高分辨率三维结构，揭示了其底物结合口袋的构象特征，并阐明了ATP水解驱动药物外排的分子机制。
2. **文献名称**：*Functional characterization of recombinant ABCG2 expressed in mammalian cells*
**作者**：Robey R.W. et al. (2018)
**摘要**：报道了在HEK293细胞中高效表达功能性ABCG2重组蛋白的方法，验证其对米托蒽醌等化疗药物的转运活性，为体外药物相互作用研究提供模型。
3. **文献名称**：*Role of N-linked glycosylation in the trafficking and stability of ABCG2*
**作者**：Diop N.K. et al. (2011)
**摘要**：利用重组ABCG2蛋白突变体，证明其N-糖基化修饰对细胞膜定位及蛋白稳定性具有关键作用，缺失糖基化会导致蛋白酶体降解途径激活。
---
**提示**：实际引用时建议通过PubMed或专业数据库(如SciFinder)检索最新文献，关注领域内权威期刊(如*Nature Communications*、*Journal of Biological Chemistry*)近年发表的研究。
ABCG2 (ATP-binding cassette subfamily G member 2), also known as breast cancer resistance protein (BCRP), is a critical transmembrane transporter protein belonging to the ATP-binding cassette (ABC) superfamily. It plays a pivotal role in cellular detoxification and multidrug resistance (MDR) by actively exporting a wide range of endogenous and exogenous substrates, including chemotherapeutic agents, toxins, and metabolic byproducts, across cellular membranes. This efflux activity relies on ATP hydrolysis, enabling ABCG2 to maintain cellular homeostasis and protect tissues from xenobiotic damage. However, its overexpression in cancer cells is a major contributor to therapy resistance, as it reduces intracellular drug accumulation.
Recombinant ABCG2 protein is engineered through heterologous expression systems (e.g., insect, mammalian, or yeast cells) to study its structure-function relationships, transport mechanisms, and interactions with inhibitors. Purification often involves affinity tags (e.g., His-tag) and advanced chromatography techniques. The recombinant form retains native conformation and ATPase activity, enabling in vitro assays to screen modulators or probe substrate specificity. Structural studies using cryo-EM and X-ray crystallography have revealed its dimeric architecture and nucleotide-binding domain dynamics, offering insights for drug design. Research on ABCG2 recombinant protein also extends to understanding its role in pharmacokinetics, particularly in blood-brain barrier penetration and placental drug transport, impacting drug development and precision medicine strategies.
×
